KRAS and neoplasm: Hyperactivation of the oncogenic K-RAS signaling pathway endows PDAC tumor cells with synergistic compensatory pathway co-activation, increased RAS signaling network plasticity, and genomic and systemic adaptability, culminating in aggressive tumor growth, resistance to cytotoxic agents, systemic metastasis, and poor clinical outcomes [6,37,69,71,84].